Population Pharmacokinetics and Exposure‐Response Analyses for the Most Frequent Adverse Events Following Treatment With Lemborexant, an Orexin Receptor Antagonist, in Subjects With Insomnia Disorder

Lemborexant is a novel orexin receptor antagonist approved in the United States and Japan for the treatment of insomnia. This article describes the population pharmacokinetics (PK) of lemborexant and the relationship of its daily steady‐state exposure (C(av,ss)) to the probability of most frequent t...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Pharmacol
Hlavní autoři: Lalovic, Bojan, Majid, Oneeb, Aluri, Jagadeesh, Landry, Ishani, Moline, Margaret, Hussein, Ziad
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2020
Témata:
Pharmacometrics
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7689791/
https://ncbi.nlm.nih.gov/pubmed/32666570
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.1683
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky